Suppr超能文献

肽核酸钳夹辅助荧光熔解曲线分析与肽核酸钳夹在检测伴有恶性胸腔积液的肺癌患者配对肿瘤组织、细胞块、胸腔积液及血液中的突变方面的比较

Comparison of PNA Clamping-assisted Fluorescence Melting Curve Analysis and PNA Clamping in Detecting Mutations in Matched Tumor Tissue, Cell Block, Pleural Effusion and Blood of Lung Cancer Patients With Malignant Pleural Effusion.

作者信息

Jeon Sang Hoon, Kim Hyung Woo, Kim Bit Na, Kang Nahyeon, Yeo Chang Dong, Park Chan Kwon, Kim Young Kyoon, Lee Yoon Ho, Kim Tae-Jung, Lee Kyo Young, Lee Sug Hyung, Park Jong Y, Park Mi Sun, Yim Hyeon Woo, Kim Seung Joon

机构信息

Division of Pulmonology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

The Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

出版信息

In Vivo. 2019 Mar-Apr;33(2):595-603. doi: 10.21873/invivo.11516.

Abstract

BACKGROUND/AIM: This study compared the efficacy of PANAMutyper™, a novel technology that integrates PNAClamp™ and PANA S-Melting™, and PNAClamp™ alone for the detection of EGFR mutations in lung cancer patients.

MATERIALS AND METHODS

PANAMutyper™ and PNAClamp™ were used to assess the EGFR mutation status in tissue, cell block, pleural effusion, and blood samples of 90 lung cancer patients with malignant pleural effusion.

RESULTS

PANAMutyper™ detected more EGFR mutations than PNAClamp™, especially in body fluids (pleural effusion and serum). Patients with additional EGFR mutations detected using PANAMutyper™ had a favorable response to EGFR-tyrosine kinase inhibitor (TKI) treatment.

CONCLUSION

The diagnostic performance of PANAMutyper™ was superior to that of PNAClamp™ for the detection of EGFR mutations. It was also better at identifying lung cancer patients with malignant pleural effusion who were likely to benefit from EGFR-TKI treatment.

摘要

背景/目的:本研究比较了整合了PNAClamp™和PANA S-Melting™的新技术PANAMutyper™与单独使用PNAClamp™检测肺癌患者表皮生长因子受体(EGFR)突变的效果。

材料与方法

使用PANAMutyper™和PNAClamp™评估90例伴有恶性胸腔积液的肺癌患者的组织、细胞块、胸腔积液及血液样本中的EGFR突变状态。

结果

PANAMutyper™检测到的EGFR突变比PNAClamp™更多,尤其是在体液(胸腔积液和血清)中。使用PANAMutyper™检测到额外EGFR突变的患者对EGFR酪氨酸激酶抑制剂(TKI)治疗有良好反应。

结论

在检测EGFR突变方面,PANAMutyper™的诊断性能优于PNAClamp™。在识别可能从EGFR-TKI治疗中获益的伴有恶性胸腔积液的肺癌患者方面,它也表现更佳。

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验